IRF3 and cancer: In cancer cells with HER2 mutations, HER2 combines with STING and recruits the kinase AKT1 to phosphorylate TBK1, thus preventing the interaction between STING‐TBK1 and TBK1‐IRF3, ultimately shielding cancer cells from host antitumor immunity.235